Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Carasent AB (publ)LTS:0H9M 80 EBITDA Margin % is 15.13% as of Jun. 2026, which is 25% below its 10-year median of 20.21. GuruFocus rates LTS:0H9M with a GF Score™ of 80/100 and a GF Value™ of kr24.22. The stock has 3 warning signs investors should review. Among 664 Healthcare Providers & Services companies, Carasent AB (publ) ranks better than 80.57% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Carasent AB (publ)'s EBITDA for the
three
months ended in Jun. 2026 was kr14.9 Mil. Carasent AB (publ)'s Revenue for the
three
months ended in Jun. 2026 was kr98.4 Mil. Therefore, Carasent AB (publ)'s EBITDA margin for the quarter that ended in Jun. 2026 was 15.13%.
Carasent AB (publ) (LTS:0H9M) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Carasent AB (publ) EBITDA Margin % Related Terms
Carasent AB (publ) EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Carasent AB (publ)'s EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0H9M vs VEEV, BTSG, TEM: EBITDA Margin % Comparison
For the Health Information Services subindustry, Carasent AB (publ)'s EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Carasent AB (publ) EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Carasent AB (publ)'s EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Carasent AB (publ)'s EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Carasent AB (publ) (LTS:0H9M) has a EBITDA Margin % of 15.13% as of Jun. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Carasent AB (publ) and its competitors. This is 25% below median its historical median of 20.21. According to the industry distribution chart, Carasent AB (publ) ranks #129 out of 664 companies in the Healthcare Providers & Services industry, placing it in the top 19.4%.
Is Carasent AB (publ)'s EBITDA Margin % too high?
Carasent AB (publ)'s current EBITDA Margin % of 15.13% is 25% below median its 10-year median of 20.21. The Healthcare Providers & Services industry median EBITDA Margin % is 10.21. Carasent AB (publ)'s value of 15.13% is 48.2% above this industry median. Based on the distribution chart, Carasent AB (publ) ranks #129 out of 664 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Carasent AB (publ) has a GF Score™ of 80/100, reflecting its overall financial health beyond just this single metric.
How does Carasent AB (publ)'s EBITDA Margin % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Carasent AB (publ) ranks #129 out of 664 companies for EBITDA Margin %. This places Carasent AB (publ) in the top 19% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 10.21. Carasent AB (publ)'s value of 15.13% is 48.2% above this benchmark. While the company's 10-year median is 20.21 vs. the industry median of 10.21, Carasent AB (publ) has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.21, based on 664 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Carasent AB (publ)'s current EBITDA Margin % of 15.13% is 48.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Carasent AB (publ) and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Carasent AB (publ)'s current EBITDA Margin % is 15.13%, which is 25% below median its own 10-year median of 20.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Carasent AB (publ) stock overvalued right now?
Carasent AB (publ) (LTS:0H9M) has a current EBITDA Margin % of 15.13%. The stock's GF Value™ is kr24.22, compared to a current price of kr20.60 — trading 14.9% below its estimated fair value. The current EBITDA Margin % is 15.13%, which is 25% below median its 10-year median of 20.21 and 48.2% above the Healthcare Providers & Services industry median of 10.21. Carasent AB (publ)'s overall GF Score™ is 80/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Carasent AB (publ) (LTS:0H9M), the current EBITDA Margin % is 15.13% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Carasent AB (publ) (LTS:0H9M) Overvalued in 2026?
Based on GuruFocus' analysis, Carasent AB (publ) stock appears to be undervalued.
The current stock price of kr20.60 is trading 14.9% below its estimated GF Value™ of kr24.22.
Key valuation signals for LTS:0H9M:
EBITDA Margin %: 15.13% (25% below median its 10-year median of 20.21)
GF Value™: kr24.22 vs. price of kr20.60 (14.9% below fair value)
Industry Position: 48.2% above the Healthcare Providers & Services median (#129 of 664)
No single metric tells the full story. See the LTS:0H9M stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Carasent AB (publ) Formerly Carasent AB is a comprehensive provider of cloudbased EHR solutions and platform services for various organizations within the healthcare sector. With Webdoc as the main product, the group offers a broad ecosystem of services, including solutions for patient communication and business intelligence. Geographically, the company operates in the Nordic region and Germany. It derives maximum revenue from Nordic Region. The solutions provides by the group are: Webdoc; Metodika; Medrave; HPI plustoo; Ad Curis; Ad Opus; Webcur; Data-AL; and Data-Cur.
80GF Score
Get the complete analysis for LTS:0H9M
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0H9M has been successfully added to your 
